Treating to target in major depressive disorder: Response to remission to functional recovery

CNS Spectrums

Volumn 20, Issue S1, 2015, Pages 20-30

  McIntyre, Roger S ^a   Lee, Yena ^a   Mansur, Rodrigo B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

antidepressant; cognition; depression; target; treatment resistant

Indexed keywords

ARIPIPRAZOLE; BREXPIPRAZOLE; KETAMINE; VORTIOXETINE;

ALTERNATIVE MEDICINE; COGNITION; CONVALESCENCE; DRUG EFFICACY; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MEDICAL INFORMATICS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; TELEHEALTH; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESISTANT DEPRESSION; DEPRESSIVE DISORDER, MAJOR; MULTIMODALITY CANCER THERAPY; REMISSION;

COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; HUMANS; RECOVERY OF FUNCTION; REMISSION INDUCTION;

EID: 84951056430     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852915000826     Document Type: Review

References (107)

1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995): 743-800.
2. Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012; 35(1): 1-14.
3. McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry. 2004; 49(3 Suppl 1): 10S-16S.
4. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015; 76(2): 155-162.
5. Cashin P, Sahay R. Internal migration, center-state grants, and economic growth in the states of India. Staff Papers (International Monetary Fund). 1996; 43(1): 123-171.
6. Sahakian BJ, Bruhl AB, Cook J, et al. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people. Philos Trans R Soc Lond B Biol Sci. 2015; 370(1677): 20140214.
7. Collins PY, Insel TR, Chockalingam A, Daar A, Maddox YT. Grand challenges in global mental health: integration in research, policy, and practice. PLoS Med. 2013; 10(4): e1001434.
8. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011; 475(7354): 27-30.
9. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry. 1991; 48(9): 796-800.
10. McIntyre RS, Fallu A, Konarski JZ. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther. 2006; 28(11): 1882-1891.
11. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000; 157(9): 1501-1504.
12. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000; 57(4): 375-380.
13. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR∗D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009; 60(11): 1439-1445.
14. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991; 48(9): 851-855.
15. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011; 41(6): 1165-1174.
16. Mojtabai R. Residual symptoms and impairment in major depression in the community. Am J Psychiatry. 2001; 158(10): 1645-1651.
17. Zimmerman M, Posternak MA, Chelminski I. Using a self-report depression scale to identify remission in depressed outpatients. Am J Psychiatry. 2004; 161(10): 1911-1913.
18. Trivedi MH, Morris DW, Wisniewski SR, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013; 170(6): 633-641.
19. McIntyre RS. Using measurement strategies to identify and monitor residual symptoms. J Clin Psychiatry. 2013; 74(Suppl 2): 14-18.
20. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013; 30(6): 515-527.
21. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009; 374(9690): 609-619.
22. Harding KJ, Rush AJ, Arbuckle M, Trivedi MH, Pincus HA. Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry. 2011; 72(8): 1136-1143.
23. McIntyre RS, Konarski JZ, Gupta S. Editorial: sharpening the focus in mood disorders: from disease models to individualized measurementbased care. Ann Clin Psychiatry. 2007; 19(4): 213-214.
24. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR∗D: implications for clinical practice. Am J Psychiatry. 2006; 163(1): 28-40.
25. Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry. 2012; 57(12): 782-788.
26. Szegedi A, Jansen WT, Van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009; 70(3): 344-353.
27. Harmer CJ, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009; 166(10): 1178-1184.
28. Uher R, Mors O, Rietschel M, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry. 2011; 72(11): 1478-1484.
29. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117(Suppl 1): S26-S43.
30. Arnow BA, Blasey C, Williams LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D Trial. Am J Psychiatry. 2015; 172(8): 743-750.
31. Schatzberg AF, De Battista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM. ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D Trial. Am J Psychiatry. 2015; 172(8): 751-759.
32. Gelenberg AJ. A review of the current guidelines for depression treatment. J Clin Psychiatry. 2010; 71(7): e15.
33. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry. 2006; 163(11): 1905-1917.
34. Han C, Wang SM, Kwak KP, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study. J Psychiatr Res. 2015; 66-67: 84-94.
35. Nelson JC, Rahman Z, Laubmeier KK, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. CNS Spectr. 2014; 19(6): 528-534.
36. Nelson JC, Thase ME, Bellocchio EE, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. 2012; 27(3): 125-133.
37. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009; 166(9): 980-991.
38. Zhou X, Keitner GI, Qin BM, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015; 18(11): pyv060.
39. McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. CNS Spectr. 2013; 18(Suppl 1): 4-20.
40. Citrome L. Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today (Barc). 2015; 51(7): 397-414.
41. Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry. 2014; 75(2): 169-177.
42. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002; 63(3): 181-186.
43. Cooper JA, Tucker VL, Papakostas GI. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol. 2014; 28(2): 118-124.
44. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology. 2009; 30(4): 497-521.
45. Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer. 2001; 9(6): 469-470.
46. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010; 167(3): 281-288.
47. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011; 168(7): 689-701.
48. Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008; 69(1): 87-94.
49. Lavretsky H, Reinlieb M St, Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial 1. Am J Psychiatry. 2015; 172(6): 561-569.
50. De Battista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003; 64(9): 1057-1064.
51. Rizvi SJ, Geraci J, Ravindran A, Kennedy SH. Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue. J Clin Psychopharmacol. 2014; 34(6): 755-759.
52. Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatmentresistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015; 76(4): e487-e498.
53. Hollon SD, De Rubeis RJ, Fawcett J, et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014; 71(10): 1157-1164.
54. De Rubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005; 62(4): 409-416.
55. Fournier JC, De Rubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010; 303(1): 47-53.
56. Hollon SD, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety. 2010; 27(10): 891-932.
57. Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry. 2002; 51(2): 123-133.
58. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR∗D report. Am J Psychiatry. 2007; 164(5): 739-752.
59. Pagnin D, de Queiroz V, V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004; 20(1): 13-20.
60. Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. Am J Psychiatry. 2012; 169(12): 1238-1244.
61. Schulze-Rauschenbach SC, Harms U, Schlaepfer TE, Maier W, Falkai P, Wagner M. Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. Br J Psychiatry. 2005; 186(5): 410-416.
62. Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry. 2003; 53(4): 324-331.
63. Grunhaus L, Dannon PN, Schreiber S, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biol Psychiatry. 2000; 47(4): 314-324.
64. Rasmussen KG. Some considerations in choosing electroconvulsive therapy versus transcranial magnetic stimulation for depression. J ECT. 2011; 27(1): 51-54.
65. Kennedy SH, Giacobbe P. Treatment resistant depression-advances in somatic therapies. Ann Clin Psychiatry. 2007; 19(4): 279-287.
66. Thachil AF, Mohan R, Bhugra D. The evidence base of complementary and alternative therapies in depression. J Affect Disord. 2007; 97(1-3): 23-35.
67. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010; 167(8): 942-948.
68. Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012; 169(12): 1267-1274.
69. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014; 9(5): e96905.
70. Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015; 76(3): 247-252.
71. Aligeti S, Quinones M, Salazar R. Rapid resolution of suicidal behavior and depression with single low-dose ketamine intravenous push even after 6 months of follow-up. J Clin Psychopharmacol. 2014; 34(4): 533-535.
72. Diazgranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatmentresistant major depressive disorder. J Clin Psychiatry. 2010; 71(12): 1605-1611.
73. Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014; 31(4): 335-343.
74. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol. 2014; 54: 119-139.
75. Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015; 5: e632.
76. Pots WT, Fledderus M, Meulenbeek PA, Ten Klooster PM, Schreurs KM, Bohlmeijer ET. Acceptance and commitment therapy as a web-based intervention for depressive symptoms: randomised controlled trial. Br J Psychiatry In press. DOI: 10.1192/bjp.bp.114.146068.
77. Kelders SM, Bohlmeijer ET, Pots WT, van Gemert-Pijnen JE. Comparing human and automated support for depression: Fractional factorial randomized controlled trial. Behav Res Ther. 2015; 72: 72-80.
78. Renton T, Tang H, Ennis N, et al. Web-based intervention programs for depression: a scoping review and evaluation. J Med Internet Res. 2014; 16(9): e209.
79. IsHak WW, Mirocha J, Pi S, et al. Patient-reported outcomes before and after treatment of major depressive disorder. Dialogues Clin Neurosci. 2014; 16(2): 171-183.
80. Papakostas GI. Components of cognitive functioning and their measurement. J Clin Psychiatry. 2015; 76(6): e16.
81. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006; 145(1): 39-48.
82. Buist-Bouwman MA, Ormel J, de Graaf R, et al. Mediators of the association between depression and role functioning. Acta Psychiatr Scand. 2008; 118(6): 451-458.
83. McIntyre RS, Soczynska JZ, Woldeyohannes HO, et al. The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015; 56: 279-282.
84. McIntyre RS, Xiao HX, Syeda K, et al. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs. 2015; 29(7): 577-589.
85. Insel TR. The NIMH Research Domain Criteria (RDoC) project: precision medicine for psychiatry. Am J Psychiatry. 2014; 171(4): 395-397.
86. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167(7): 748-751.
87. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014; 17(10): 1557-1567.
88. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol In press. DOI: 10.1093/ijnp/pyv082.
89. Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf. 2015; 14(8): 1291-1304.
90. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215-223.
91. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebocontrolled trial. Am J Psychiatry. 2007; 164(6): 900-909.
92. Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014; 39(6): 1388-1398.
93. Moskal JR, Burch R, Burgdorf JS, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 2014; 23(2): 243-254.
94. Lennox R, Porter DW, Flatt PR, Holscher C, Irwin N, Gault VA. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology. 2014; 86: 22-30.
95. McIntyre RS, Powell AM, Kaidanovich-Beilin O, et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res. 2013; 237: 164-171.
96. Goldstein BI, Carnethon MR, Matthews KA, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation In press. DOI: 10.1161/CIR.0000000000000229.
97. Liu CS, Carvalho AF, Mansur RB, McIntyre RS. Obesity and bipolar disorder: synergistic neurotoxic effects? Adv Ther. 2013; 30(11): 987-1006.
98. Lin CH, Chen CC, Wong J, McIntyre RS. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. J Affect Disord. 2014; 161: 123-126.
99. Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry. 2014; 59(7): 349-357.
100. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet. 2012; 379(9833): 2291-2299.
101. Nierenberg AA, Sylvia L, Doederlein A, et al. Improving the care of patients who have treatment-resistant depression: the promise of the PCORnet Mood Network. J Clin Psychiatry. 2015; 76(4): e528-e530.
102. Kucyi A, Alsuwaidan MT, Liauw SS, McIntyre RS. Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder. Postgrad Med. 2010; 122(6): 107-116.
103. Masley S, Roetzheim R, Gualtieri T. Aerobic exercise enhances cognitive flexibility. J Clin Psychol Med Settings. 2009; 16(2): 186-193.
104. Davis CL, Tomporowski PD, Boyle CA, et al. Effects of aerobic exercise on overweight children's cognitive functioning: a randomized controlled trial. Res Q Exerc Sport. 2007; 78(5): 510-519.
105. Kubesch S, Bretschneider V, Freudenmann R, et al. Aerobic endurance exercise improves executive functions in depressed patients. J Clin Psychiatry. 2003; 64(9): 1005-1012.
106. Shay KA, Roth DL. Association between aerobic fitness and visuospatial performance in healthy older adults. Psychol Aging. 1992; 7(1): 15-24.
107. Shelton RC, Trivedi MH. Using algorithms and computerized decision support systems to treat major depression. J Clin Psychiatry. 2011; 72(12): e36.